Sandoz Files US Trastuzumab With EirGenix
Five Separate Herceptin Biosimilars Are Already Competing In US Market
Executive Summary
Sandoz has filed the proposed trastuzumab biosimilar developed by partner EirGenix with the US FDA. If approved, the product will have to compete in an already busy market for Herceptin biosimilars.